Dublin, March 30, 2015 (GLOBE NEWSWIRE) -- Research and Markets (http://www.researchandmarkets.com/research/99dwg9/blood_screening) has announced the addition of the "Blood Screening Market by Technology (Nucleic Acid Amplification Test, ELISA, Rapid Test, Chemiluminescence Immunoassay, Next Generation Sequencing, Western Blotting), Product (Instrument, Reagent) & End User (Blood Bank, Hospital) - Forecasts to 2019 " report to their offering.
The blood screening market is expected to reach $2.55 billion by 2019 from $1.5 billion in 2014, growing at a CAGR of 10.4% from 2014 to 2019. The global market is segmented on the basis of products and services, technologies, end users, and regions.
The blood screening market is a growing field that has witnessed a number of technological advancements since its inception, such as a shift from first-generation ELISA to advanced NAT technologies. This market is driven by several factors including increasing number of blood donations and blood donors, rising awareness regarding the safety of donated blood, increasing patient affordability, increasing adoption of NAT, and rising demand of donated blood. However, factors such as high capital expenditure and operating cost of NAT and stringent regulatory approval processes are likely to hinder the growth of this market. The blood screening market in Asia is likely to provide an array of opportunities owing to the growing demand for donated blood, increasing disposable income (leading to adoption of NAT ), and increased focus of key players in the Asian region.
On the basis of products and services, the global market is segmented into instruments (hardware), reagents, and software and services. The blood screening instruments market is further segmented into rental purchase and outright purchase; while the blood screening reagents market segment is classified into ELISA reagents, NAT reagents, and other reagents.
On the basis of technologies, the global global market is segmented into nucleic acid tests (NAT), enzyme-linked immunosorbent assays (ELISA), enzyme immunoassays (EIAs) and chemiluminescent immunoassays (CLIAs), next-generation sequencing (NGS), and Western blot assays. The blood screening NAT market is further segmented into transcription mediated amplification (TMA) and real-time PCR. The blood screening market for ELISA testing is further categorized into card methodology, first-generation, second-generation, third-generation, and fourth-generation ELISA.
Based on end users, the blood screening market is segmented into blood banks and hospitals.
Key Topics Covered:
1 Introduction
2 Research Methodology
3 Executive Summary
4 Premium Insights
5 Market Overview
6 Industry Trends
7 Blood Screening Market, By Technology
8 Blood Screening Market, By Products and Services
9 Blood Screening Market, By End User
10 Blood Screening Market, By Region
11 Competitive Landscape
12 Company Profiles
- Abbott Laboratories
- Beckman Coulter (Subsidiary of Danaher Corporation)
- Becton, Dickinson and Company
- Bio-Rad Laboratories, Inc.
- Biomérieux
- Grifols
- Ortho-Clinical Diagnostics, Inc.
- Roche Diagnostics (A Division of F. Hoffmann-La Roche Ltd)
- Siemens Healthcare (Subsidiary of Siemens AG)
- Thermo Fisher Scientific, Inc.
For more information visit http://www.researchandmarkets.com/research/99dwg9/blood_screening